#United States #biotechnology #Boulder #muscle diseases #Edgewise Therapeutics

Edgewise Therapeutics Set to Present at Guggenheim Biotech Summit 2026

On February 12, 2026, Edgewise Therapeutics, Inc., a prominent player in the biopharmaceutical sector focused on muscle diseases, will be participating in the Guggenheim Emerging Outlook Biotech Summit. This highly anticipated event will take place at 3:00 PM ET, featuring a vital presentation by Dr. Behrad Derakhshan, the Chief Operating Officer of the company.

The presentation marks an essential opportunity for Edgewise to share its latest insights and advancements in the treatment of muscle disorders. Interested viewers can catch the live webcast of the event, accessible through the Edgewise Events Presentations page. A replay will also be available for a limited time after the conference, allowing for broader engagement with Edgewise's groundbreaking work.

About Edgewise Therapeutics

Founded with a mission to transform the lives of patients suffering from severe muscle diseases, Edgewise Therapeutics has carved a niche in developing pioneering therapies. Notably, the company has focused on therapeutic candidates designed to address conditions such as Becker and Duchenne muscular dystrophies as well as serious cardiac issues.

One of its flagship products, Sevasemten, is a first-in-class fast skeletal myosin inhibitor that is currently in late-stage clinical trials aimed at combating the challenges posed by muscular dystrophies. This oral medication adds a breakthrough element to the treatment landscape, offering hope to those affected by these debilitating conditions.

Moreover, Edgewise is pushing boundaries in cardiac health with investigational drugs like EDG-7500, a novel cardiac sarcomere modulator under Phase 2 development targeting hypertrophic cardiomyopathy. Another exciting candidate, EDG-15400, is making its way through Phase 1 trials for heart failure treatment. These innovations exemplify Edgewise's commitment to leveraging its expertise in muscle physiology to develop effective new therapies.

The annual Guggenheim Biotech Summit serves as a forum for stakeholders in the biotechnology sector to converge, share knowledge, and explore advancements in health-related science. It attracts a diverse demographic of professionals, from investors to academic researchers, providing a streamlined platform for knowledge exchange and relationship building.

As Edgewise Therapeutics gears up for this year’s summit, the focus will not only be on the groundbreaking products in their pipeline but also on reinforcing the company's dedication to transforming the patient experience through rigorous research and development efforts. The entire team at Edgewise is unified in their mission to assist patients and families impacted by these challenging conditions, ensuring that their groundbreaking work translates into meaningful change.

To stay updated on their journey, visit the official Edgewise Therapeutics website or follow them on LinkedIn and X for the latest news and insights. Edgewise Therapeutics is set on a transformative path in addressing serious muscle diseases, and participation in events like the Guggenheim Biotech Summit plays a crucial role in that mission.